378 results about "Otitis" patented technology

The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (k_on) of at least 2×10⁵ M⁻¹s⁻¹ and a dissociation rate (k_off) of less than 5×10⁻⁴ s⁻¹.

The invention provides an ophthalmic, otic or nasal pharmaceutical composition, comprising levofloxacin or the pharmaceutical acceptable salts thereof and loteprednol etabonate, wherein the weight ratio of loteprednol etabonate to levofloxacin is 1:0.2-5. The use of ophthalmic, otic or nasal pharmaceutical composition of the invention in preparation of the medication for treatment of conjunctivitis, keratitis, blepharitis, dacrycystitis, hordeolum, corneal ulcer and ocular infection accompanied with ophthalmitis and even inflammation of the surrounding tissues, to prevent increase of bacterial infection risks and the tissue inflammation of the infected area after the ophthalmic surgeries or ocular injuries, to treat or alleviate the bacterial infection in combination with the tissue inflammation of the infected area, or to treat tympanitis, otitis externa and infective rhinitis.

This invention relates to a synthetic nutritional composition suitable for use in the prevention of secondary infections following a viral infection characterised by neuraminidase activity comprising a sialylated oligosaccharide and N-acetyl-lactosamine and/or an oligosaccharide containing N-acetyl-lactosamine The invention further extends to the use of such a composition in the prevention of secondary infections such as otitis media.

The present invention provides peptides and analogs and derivatives thereof having antimicrobial activity at least against Streptococcus uberis for the treatment of a range of infectious disease mastitis, otitis externa, clostridial intestinal disease and respiratory disease.

This invention relates to a method of treating otitis externa, and in particular otitis externa of fungal etiology, using topical medication, including antifungal agents such as, for example fluconazole, voriconazole, itraconazole, clotrimazole, amphotericin B, caspofungin (Cancidas®), micafungin (Mycamine®), terbinafine, naftifine, butenafine, amorolfine, ravuconazole, posaconazole, flucytosine, econazole, enilaconazole, miconazole, oxiconazole, saperconazole, sulconazole, terconazole, tioconazole, nikkomycin Z, anidulafungin (LY303366), nystatin, pimaricin, griseofulvin, ciclopirox, haloprogin, tolnaftate, and undecylenate.

The present invention relates to a formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, and antifungal, and an anti-inflammatory in a thick, otic carrier. In one embodiment, the formulation comprises a therapeutically effective amount of active ingredients including a fluoroquinolone, a triazole antifungal, a thiocarbamate antifungal, a corticosteroid and a polyene antifungal, as well as a thickener such that the formulation, upon applying to the infected ear canal, gels and remains in the ear canal, continuously releasing the active ingredients for several days, achieving consistent complete (98-100%) clinical resolution of otomycosis and otitis externa in a single application.

The invention discloses the structure of four novel bakkenolide compounds extracted from Petasites tricholobus Franch. having a formula (1), the process for extraction and separation, and the use of the compounds in preparing medicament for the treatment and prevention of diseases possibly related to theramine and/or leukotrienes constituents, including asthma, allergic rhinitis, nasal sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, chronic infectious arthritis, enteropathy, nervous disease and otitis.

A diagnosis-and-display integrated optical tomographic imaging otoscope for examining otitis media. A hollow casing includes an ear specular disposed on a front surface, a display including an LCD disposed on a rear surface, and a manipulating handle on a lower part. An image-photographing part includes a CCD camera inside the casing, and photographs an ear drum image of a patient through the ear specular. A section-photographing part includes a collimator and a galvanometer mirror inside the casing, and photographs section images of the ear drum and a middle ear of the patient. The ear drum image obtained by the image-photographing part and the section images of the ear drum and the middle ear are obtained in a non-incision method by the section-photographing part, and are displayed in real time on the LCD such that desirable images can be stored.

A method of aiding the diagnosis of otitis media in a patient includes obtaining image data in a processor apparatus of a computing device, the image data being associated with at least one electronic image of a tympanic membrane of the patient, calculating a plurality of image features, each image feature being calculated based on at least a portion of the image data, classifying the at least one electronic image as a particular type of otitis media using the plurality of image features, and outputting an indication of the particular type of otitis media. Also, a system for implementing such a method that includes an output device and a computing device.

This invention relates to a method of treating otitis externa using a topical combination medication, including one or more antifungal agent such as, for example fluconazole, voriconazole, itraconazole, clotrimazole, amphotericin B, caspofungin, micafungin, terbinafine, naftifine, butenafine, amorolfine, ravuconazole, posaconazole, flucytosine, econazole, enilaconazole, miconazole, oxiconazole, saperconazole, sulconazole, terconazole, tioconazole, nikkomycin Z, anidulafungin (LY303366), nystatin, pimaricin, griseofulvin, ciclopirox, haloprogin, tolnaftate, and undecylenate and one or more antibacterial agent such as neomycin sulfate, polymyxin B sulfate, colistin sulfate, gentamycin, tobramycin, chloramphenicol, Ciprofloxacin, Ofloxacin, a penicillin compound, a cephalosporin compound, a macrolide compound, a fluoroquinolone compound, streptomycin, or kanamycin.

The inventions discloses a composition comprising at least one N-acetyl lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, for use in preventing acute respiratory infections (ARI) and/or relieving symptoms of said ARI infections. Preferably said composition is a starter infant formula. Said acute respiratory infection is in particular bronchiolitis or otitis.

The present invention relates to the use of plasminogen/plasmin and its derivatives as agents for enhancing host defense against infection or other infectious diseases. The invention also relates to a method for screening of compounds which enhance host defense against infection by evaluating the host defense against bacterial arthritis and spontaneous otitis media in an animal model.

The invention provides a preparation method of a Traditional Chinese medicament for treating swelling tympanitis in an external auditory meatus, and belongs to the technical field of a preparation method of a Traditional Chinese medicament. Sulfonamides and antibiotics are usually used for treating swelling tympanitis in the external auditory meatus; and if using penicillin, a skin test needs to be performed before use, and a positive person is not allowed to use. The Traditional Chinese medicament is prepared from the following bulk drugs: Chinese mahonia leaf, tender catchweed bedstraw herb, dysosma versipellis, Indian stringbush root, herb saururus chinensis, garden erphorbia herb, longhairy antenoron herb, omoto nipponlily root and rhizome, climbing groundsel herb, all-grass of snakefoot clubmoss, Japanese stephania root, thymifoious euphorbia herb, Chinese brake herb, fruit of tree-of-heaven ailanthus, magnolia flower, dahurian angelica, ginger, cocklebur fruit, chastetree fruit, ligusticum sinense, peppermint, lindley butterflybush herb, cicada slough, scabrous patrinia root, centipeda minima, perilla leaf, fistular onion stalk, notoperygium root and liquorice. The preparation method comprises the following steps: soaking the 29 bulk drugs in water; decocting with slow fire; and filtering to remove residues to obtain decoction, namely the Traditional Chinese medicament for treating swelling tympanitis in the external auditory meatus. The Traditional Chinese medicament has the advantages of simple preparation process, short course of treatment, high cure rate and capability of avoiding adverse reaction caused by western medicaments.

The invention provides a composition containing an effective dose of antofloxacin or a pharmaceutically acceptable salt thereof or/and an effective dose of an anti-inflammatory steroid or non-steroidanti-inflammatory medicine or/and an effective dose of a water-retaining or wetting agent or an anti-xerophthalmia medicine, and an application of the composition in the preparation of an externally used antofloxacin medicine for local eyes or ears or noses or skins, used for preventing or treating conjunctivitis, angular blepharitis, keratitis, scleritis, trachoma, xerophthalmia, cataract, otitisexterna, otitis media, folliculitis and impetigo in humans or mammals. The medicine obtained in the invention has good curative effects or good therapeutic compliance.

The present invention provides a liquid preparation composition comprising a solvent and a surfactant dissolving in the solvent, the surface tension of the liquid preparation composition is less than 60mN / m, and the pH of the liquid preparation composition is 5.0-7.4. The present invention also discloses a preparation method of the liquid preparation composition and use of the liquid preparation composition in treatment of otitis media, otitis externa, rhinitis, nasosinusitis, lower respiratory tract inflammation, xerostomia, xerophthalmia and dry noses. The present invention also discloses a preparation comprising the liquid preparation composition. The liquid preparation composition can effectively relieve the otitis media, the otitis externa, the rhinitis, the nasosinusitis, the lower respiratory tract inflammation, the xerostomia, the xerophthalmia, the dry noses and other symptoms, can be used in the form of sprays or liquid droplets, can be applied to an effective site without use of a propellant or an atomization device, is easy to operate, and can effectively avoid stimulation and injury caused by the propellant and use inconvenience of the atomization device.

Pharmacological test shows that the externally-used preparation of Cetirizine has ideal allergy resistant and anti-inflammatory action to the rat passive cutaneous anaphylaxis (Rat PCA) model and dimethylbenzene caused mouse otitis model, and also prevents the adverse effect to the central system caused by whole body administration. It is also found in the test, that the externally used preparation of Cetirizine also has very fine inhibitory action to dinitrofluorobenzene caused mouse porphyria hypersensitivity (PTH), the novel pharmacological action of the Cetirizine shows that the Cetirizine external preparation has good therapeutic action to skin inflammations which mainly include porphyria hypersensitivity.

The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.